Patient capital for early-stage therapeutics, backed by Taiho Pharmaceutical.
Taiho Ventures deploys $400M from Taiho Pharmaceutical’s balance sheet into preclinical-to-proof-of-concept programs in oncology, immunology, and urology.
We are typically brought into syndicates as a strategic participant. Our presence signals that a credible global pharmaceutical partner believes in the science, and may ultimately license, co-develop, or acquire the asset.
- Fund size
- $400M Expanded 2024
- Stage
- Preclinical → PoC
- Therapeutic areas
- Oncology · Immunology · Urology
- Models
- Syndicate · Build-to-buy · Spin-out
- Geography
- North America · EU · Japan
- Commitment
- Single-team, single-balance-sheet
Three plans, one balance sheet.
We are a single team underwriting three flavors of risk. Each has its own diligence cadence, its own check size, and its own definition of success. We do not pretend they are the same.
- I.Research → Pre-IND
Capital and scientific direction at the earliest stage.
Seed and Series A participation in companies still validating biology. We expect to be wrong on a meaningful share of these. Conviction is built program-by-program, not platform-by-platform.
Lead or co-lead · Board observer - II.IND → Proof of concept
Clinical-stage syndicates where we de-risk transitions.
Series B and C participation in companies moving from preclinical confidence to first human readouts. We bring regulatory, manufacturing, and operational pattern-matching from a parent that has run the same gauntlet many times.
Strategic participant · Cap-table signal - III.Build-to-buy
Company creation and spin-outs aligned with Taiho’s direction.
Selectively, we form NewCos and back spin-outs structured for clean acquisition by Taiho Pharmaceutical at a defined milestone. Terms are visible to founders from day one. There are no surprises.
Founder · Lead investor · Defined option
“A bridge between breakthrough science and global commercialization — patient where venture is impatient, clinical where biotech is theoretical.”
— TVL Investment Memo, 2026
Selected positions.
A representative slice of active and exited positions. The full portfolio (32 companies, 6 active funds) is shared on request.
- 04 / 18
Harpoon Therapeutics
Syndicate position in a clinical-stage T-cell engager platform. Participated alongside a deep specialist syndicate; brought regulatory and CMC pattern-matching from the parent.
- Year
- 2018
- Stage
- Series B
- Area
- T-cell engagers
- Model
- Syndicate
- Co-investors
- ARCH · NEA · New Leaf
- 07 / 19
Cullinan Pearl
NewCo carved out of Cullinan Oncology to advance a Taiho-originated EGFR exon 20 program. Acquired by Taiho Pharmaceutical in 2023 at a defined milestone.
- Year
- 2019
- Stage
- Build-to-buy
- Area
- Pancreatic & gastric oncology
- Model
- Build-to-buy
- Co-investors
- Cullinan Oncology
- 11 / 20
Arcus Biosciences
Late-stage participation paired with a Taiho commercialization arrangement covering Japan and select Asian markets. Capital and a real channel, in one transaction.
- Year
- 2020
- Stage
- Public follow-on
- Area
- Immuno-oncology
- Model
- Asia bridge
- Co-investors
- Gilead · Astellas
- 14 / 21
Orna Therapeutics
Platform-stage participation in a circular RNA company building a new modality. Underwritten as a multi-program option, not a single asset.
- Year
- 2021
- Stage
- Series B
- Area
- Circular RNA
- Model
- Platform
- Co-investors
- MPM · RA Capital · F-Prime
What the parent brings — beyond the check.
Taiho Pharmaceutical has been developing oncology, immunology, and urology medicines for sixty years. Capital is the visible part of our participation; the rest is operational, regulatory, and commercial infrastructure that takes a global pharma decades to build.
For founders, this looks like real conversations with experienced regulatory leads, candid manufacturing diligence well before a Phase II readout, and — when the science is a fit — a defined path to Asian commercialization without a separate, distracting partnership cycle.